2BBBullish & Bearish
Cytokinetics, Incorporated (CYTK) trades on NASDAQ. It operates in the Health Care sector, Biotechnology industry. Its current 2BB score is 47 out of 100.
Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.
Cytokinetics, Incorporated’s current 2BB score is 47 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|---|---|
| Activity | 67 | High |
| Momentum | 47 | Stable |
| Financial strength | 12 | Very Weak |
| Quality | 100 | Very Strong |
| Risk | 48 | Moderate |
| CEO | Robert I. Blum | Robert I. Blum |
| Headquarters | South San Francisco, California, United States |
| Founded | 1997 |
| Employees | 673 |
| 52-week range | $35.22 – $88.31 |
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|---|---|---|---|
| 2027-02-22 | — | -1.494 | — | $59.40M |
| 2026-11-03 | — | -1.498 | — | $40.56M |
| 2026-08-06 | — | -1.6732 | — | $17.73M |
| 2026-05-05 | -1.67 | -1.6859 | $19.36M | $8.69M |